These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 28091972)

  • 1. [Secondary prevention with antiplatelet therapy in cardiac rehabilitation].
    Wanitschek MM; Alber HF
    Wien Med Wochenschr; 2018 Feb; 168(1-2):16-22. PubMed ID: 28091972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of rivaroxaban for the secondary prevention following acute coronary syndromes among biomarker-positive patients: Insights from the ATLAS ACS 2-TIMI 51 trial.
    Korjian S; Braunwald E; Daaboul Y; Verheugt F; Bode C; Tendera M; Jain P; Plotnikov A; Burton P; Gibson CM
    Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):186-193. PubMed ID: 29249166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet Therapy for Secondary Prevention After Acute Myocardial Infarction.
    Cavallari I; Bonaca MP
    Interv Cardiol Clin; 2017 Jan; 6(1):119-129. PubMed ID: 27886815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential role of prasugrel in secondary prevention of ischemic events in patients with acute coronary syndromes.
    Toth PP
    Postgrad Med; 2009 Jan; 121(1):59-72. PubMed ID: 19179814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lights and shadows of long-term dual antiplatelet therapy in "real life" clinical scenarios.
    Scherillo M; Cirillo P; Formigli D; Bonzani G; Calabrò P; Capogrosso P; Caso P; Esposito G; Farina R; Golino P; Lanzillo T; Mascia F; Mauro C; Piscione F; Sibilio G; Tuccillo B; Villari B; Trimarco B
    J Thromb Thrombolysis; 2018 Nov; 46(4):559-569. PubMed ID: 29943351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes in high-risk patients with non-ST-segment elevation myocardial infarction.
    Cohen M
    J Thromb Thrombolysis; 2016 Apr; 41(3):464-74. PubMed ID: 26001907
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Developments in antiplatelet therapy for acute coronary syndromes and considerations for long-term management.
    Cowley MJ; Kuritzky L
    Curr Med Res Opin; 2009 Jun; 25(6):1477-90. PubMed ID: 19419337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving long-term ACS management: is there a role for the new antiplatelets?
    Cohen M
    J Interv Cardiol; 2012 Oct; 25(5):425-32. PubMed ID: 22574644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiplatelet therapy for secondary prevention of acute coronary syndrome, transient ischemic attack, and noncardioembolic stroke in an era of cost containment.
    Kessler C; Thomas K; Kao J
    J Investig Med; 2012 Jun; 60(5):792-800. PubMed ID: 22460233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term versus short-term dual antiplatelet therapy was similarly associated with a lower risk of death, stroke, or infarction in patients with acute coronary syndrome regardless of underlying kidney disease.
    Carrero JJ; Varenhorst C; Jensevik K; Szummer K; Lagerqvist B; Evans M; Spaak J; Held C; James S; Jernberg T
    Kidney Int; 2017 Jan; 91(1):216-226. PubMed ID: 27865441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The potential role of anticoagulant therapy for the secondary prevention of ischemic events post-acute coronary syndrome.
    Camuglia AC; Waddell-Smith KE; Hammett CJ; Aylward PE
    Curr Med Res Opin; 2014 Nov; 30(11):2151-67. PubMed ID: 25140867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction.
    Saraf S; Christopoulos C; Salha IB; Stott DJ; Gorog DA
    J Am Coll Cardiol; 2010 May; 55(19):2107-15. PubMed ID: 20447533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor responsiveness to antiplatelet drugs in acute coronary syndromes: clinical relevance and management.
    Reny JL; Bonvini RF; Bonvini JM; Roffi M; Fontana P
    Cardiovasc Ther; 2012 Feb; 30(1):e41-50. PubMed ID: 21073667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiac rehabilitation programme as a non-pharmacological platelet inhibitory tool in acute coronary syndrome survivors.
    Tóth-Zsámboki E; Horváth Z; Hajtman L; Leé S; Pállinger É; Kuklis E; Tahy Á; Fekete G; Kohut L; Kiss RG
    Eur J Prev Cardiol; 2017 Jul; 24(11):1148-1156. PubMed ID: 28438028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insights into the role of thrombin in the pathogenesis of recurrent ischaemia after acute coronary syndrome.
    Weitz JI
    Thromb Haemost; 2014 Nov; 112(5):924-31. PubMed ID: 25030773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.
    Reaume KT; Regal RE; Dorsch MP
    Ann Pharmacother; 2008 Apr; 42(4):550-7. PubMed ID: 18319394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.